On May 1, Motif announced a multi-year semiconductor supply partnership with MintNeuro, securing purpose-built low-power neural interface chips for its DOT implant platform. The announcement followed Motif's late-April FDA clearance to begin RESONATE, its first clinical trial for treatment-resistant depression. Locking in a dedicated IC supply arrangement this early suggests the company is building toward pivotal scale. Motif's implant operates under strict power and size constraints that off-the-shelf components are not designed to meet.